Nafasol

Nafasol may be available in the countries listed below.

Ingredient matches for Nafasol

Naproxen

Naproxen is reported as an ingredient of Nafasol in the following countries:

• South Africa

International Drug Name Search

Panflox

Panflox may be available in the countries listed below.

Ingredient matches for Panflox

Sparfloxacin

Sparfloxacin is reported as an ingredient of Panflox in the following countries:

• Bangladesh

International Drug Name Search

Dexan-VG

Dexan-VG may be available in the countries listed below.

Ingredient matches for Dexan-VG

Betamethasone

Betamethasone 17α-valerate (a derivative of Betamethasone) is reported as an ingredient of Dexan-VG in the following countries:

• Japan

Gentamicin

Gentamicin sulfate (a derivative of Gentamicin) is reported as an ingredient of Dexan-VG in the following countries:

• Japan

International Drug Name Search

Ulsanic

Ulsanic may be available in the countries listed below.

Ingredient matches for Ulsanic

Sucralfate

Sucralfate is reported as an ingredient of Ulsanic in the following countries:

• Hong Kong


• Israel


• South Africa


• Taiwan


• Thailand

International Drug Name Search

Acatak

Acatak may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Acatak

Fluazuron

Fluazuron is reported as an ingredient of Acatak in the following countries:

• Australia


• South Africa

International Drug Name Search

Ferrofumaraat Merck

Ferrofumaraat Merck may be available in the countries listed below.

Ingredient matches for Ferrofumaraat Merck

Ferrous Fumarate

Ferrous Fumarate is reported as an ingredient of Ferrofumaraat Merck in the following countries:

• Netherlands

International Drug Name Search

Rhinofebryl

Rhinofebryl may be available in the countries listed below.

Ingredient matches for Rhinofebryl

Chlorphenamine

Chlorphenamine maleate (a derivative of Chlorphenamine) is reported as an ingredient of Rhinofebryl in the following countries:

• Belgium


• Luxembourg

Paracetamol

Paracetamol is reported as an ingredient of Rhinofebryl in the following countries:

• Belgium


• Luxembourg

International Drug Name Search

Katya

Katya may be available in the countries listed below.

Ingredient matches for Katya

Ethinylestradiol

Ethinylestradiol is reported as an ingredient of Katya in the following countries:

• Slovakia


• United Kingdom

Gestodene

Gestodene is reported as an ingredient of Katya in the following countries:

• Slovakia


• United Kingdom

International Drug Name Search

Pronestyl

In some countries, this medicine may only be approved for veterinary use.

In the US, Pronestyl (procainamide systemic) is a member of the drug class group I antiarrhythmics and is used to treat Arrhythmia.

US matches:

• Pronestyl


• Pronestyl-SR Controlled-Release


• Pronestyl injection


• Pronestyl-SR injection


• Pronestyl-SR

Ingredient matches for Pronestyl

Procainamide

Procainamide hydrochloride (a derivative of Procainamide) is reported as an ingredient of Pronestyl in the following countries:

• Ethiopia


• India


• Ireland


• Kenya


• Luxembourg


• Taiwan


• Tanzania


• Uganda


• United Kingdom

International Drug Name Search

Nomégestrol Teva

Nomégestrol Teva may be available in the countries listed below.

Ingredient matches for Nomégestrol Teva

Nomegestrol

Nomegestrol acetate (a derivative of Nomegestrol) is reported as an ingredient of Nomégestrol Teva in the following countries:

• France

International Drug Name Search

Clozapina Generis

Clozapina Generis may be available in the countries listed below.

Ingredient matches for Clozapina Generis

Clozapine

Clozapine is reported as an ingredient of Clozapina Generis in the following countries:

• Portugal

International Drug Name Search

Neo-Pancreatinum

Neo-Pancreatinum may be available in the countries listed below.

Ingredient matches for Neo-Pancreatinum

Pancreatin

Pancreatin is reported as an ingredient of Neo-Pancreatinum in the following countries:

• Poland

International Drug Name Search

Cromosol

Cromosol may be available in the countries listed below.

Ingredient matches for Cromosol

Cromoglicic Acid

Cromoglicic Acid disodium salt (a derivative of Cromoglicic Acid) is reported as an ingredient of Cromosol in the following countries:

• Czech Republic


• Lithuania


• Poland


• Switzerland


• Tunisia

International Drug Name Search

Budesonide Norma

Budesonide Norma may be available in the countries listed below.

Ingredient matches for Budesonide Norma

Budesonide

Budesonide is reported as an ingredient of Budesonide Norma in the following countries:

• Greece

International Drug Name Search

Magnesium Verla N Konz.

Magnesium Verla N Konz. may be available in the countries listed below.

Ingredient matches for Magnesium Verla N Konz.

Magnesium Hydrogen Aspartate

Magnesium Hydrogen Aspartate dihydrate (a derivative of Magnesium Hydrogen Aspartate) is reported as an ingredient of Magnesium Verla N Konz. in the following countries:

• Germany

International Drug Name Search

Vigamoxi

Vigamoxi may be available in the countries listed below.

Ingredient matches for Vigamoxi

Moxifloxacin

Moxifloxacin hydrochloride (a derivative of Moxifloxacin) is reported as an ingredient of Vigamoxi in the following countries:

• Mexico

International Drug Name Search

Riboflavine Ratiopharm

Riboflavine Ratiopharm may be available in the countries listed below.

Ingredient matches for Riboflavine Ratiopharm

Riboflavin

Riboflavin is reported as an ingredient of Riboflavine Ratiopharm in the following countries:

• Netherlands

International Drug Name Search

Neurolax

Neurolax may be available in the countries listed below.

Ingredient matches for Neurolax

Hydroxyzine

Hydroxyzine hydrochloride (a derivative of Hydroxyzine) is reported as an ingredient of Neurolax in the following countries:

• Georgia

International Drug Name Search

Topiramato Merck

Topiramato Merck may be available in the countries listed below.

Ingredient matches for Topiramato Merck

Topiramate

Topiramate is reported as an ingredient of Topiramato Merck in the following countries:

• Spain

International Drug Name Search

Mandofen

Mandofen may be available in the countries listed below.

Ingredient matches for Mandofen

Tamoxifen

Tamoxifen citrate (a derivative of Tamoxifen) is reported as an ingredient of Mandofen in the following countries:

• Germany

International Drug Name Search

Apton

Apton may be available in the countries listed below.

Ingredient matches for Apton

Pantoprazole

Pantoprazole sodium (a derivative of Pantoprazole) is reported as an ingredient of Apton in the following countries:

• Portugal

International Drug Name Search

Asmedin

Asmedin may be available in the countries listed below.

Ingredient matches for Asmedin

Cimetidine

Cimetidine is reported as an ingredient of Asmedin in the following countries:

• Japan

International Drug Name Search

Docdomperi

Docdomperi may be available in the countries listed below.

Ingredient matches for Docdomperi

Domperidone

Domperidone maleate (a derivative of Domperidone) is reported as an ingredient of Docdomperi in the following countries:

• Belgium

International Drug Name Search

Tiagard

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Tiagard

Tiamulin

Tiamulin fumarate (a derivative of Tiamulin) is reported as an ingredient of Tiagard in the following countries:

• United States

International Drug Name Search

Nodolex

Nodolex may be available in the countries listed below.

Ingredient matches for Nodolex

Meloxicam

Meloxicam is reported as an ingredient of Nodolex in the following countries:

• Ecuador

International Drug Name Search

Eloson

Eloson may be available in the countries listed below.

Ingredient matches for Eloson

Mometasone

Mometasone 17-(2-furoate) (a derivative of Mometasone) is reported as an ingredient of Eloson in the following countries:

• China

International Drug Name Search

Oxilin

Oxilin may be available in the countries listed below.

Ingredient matches for Oxilin

Oxymetazoline

Oxymetazoline hydrochloride (a derivative of Oxymetazoline) is reported as an ingredient of Oxilin in the following countries:

• Chile


• Italy

International Drug Name Search

Navatrim

Navatrim may be available in the countries listed below.

Ingredient matches for Navatrim

Sulfamethoxazole

Sulfamethoxazole is reported as an ingredient of Navatrim in the following countries:

• Bangladesh

Trimethoprim

Trimethoprim is reported as an ingredient of Navatrim in the following countries:

• Bangladesh

International Drug Name Search

Enalapril / Hydrochloorthiazide A

Enalapril / Hydrochloorthiazide A may be available in the countries listed below.

Ingredient matches for Enalapril / Hydrochloorthiazide A

Enalapril

Enalapril maleate (a derivative of Enalapril) is reported as an ingredient of Enalapril / Hydrochloorthiazide A in the following countries:

• Netherlands

Hydrochlorothiazide

Hydrochlorothiazide is reported as an ingredient of Enalapril / Hydrochloorthiazide A in the following countries:

• Netherlands

International Drug Name Search

Carbamazepine Mylan

Carbamazepine Mylan may be available in the countries listed below.

Ingredient matches for Carbamazepine Mylan

Carbamazepine

Carbamazepine is reported as an ingredient of Carbamazepine Mylan in the following countries:

• Belgium

International Drug Name Search

Flutide Air

Flutide Air may be available in the countries listed below.

Ingredient matches for Flutide Air

Fluticasone

Fluticasone propionate (a derivative of Fluticasone) is reported as an ingredient of Flutide Air in the following countries:

• Japan

International Drug Name Search

Finastéride Alter

Finastéride Alter may be available in the countries listed below.

Ingredient matches for Finastéride Alter

Finasteride

Finasteride is reported as an ingredient of Finastéride Alter in the following countries:

• France

International Drug Name Search

Lanato C

Lanato C may be available in the countries listed below.

Ingredient matches for Lanato C

Lanatoside C

Lanatoside C is reported as an ingredient of Lanato C in the following countries:

• Japan

International Drug Name Search

Pantoprazol Kern Pharma

Pantoprazol Kern Pharma may be available in the countries listed below.

Ingredient matches for Pantoprazol Kern Pharma

Pantoprazole

Pantoprazole sodium (a derivative of Pantoprazole) is reported as an ingredient of Pantoprazol Kern Pharma in the following countries:

• Spain

International Drug Name Search

Feofol

Feofol may be available in the countries listed below.

Ingredient matches for Feofol

Ferrous Sulfate

Ferrous Sulfate is reported as an ingredient of Feofol in the following countries:

• Greece

Folic Acid

Folic Acid is reported as an ingredient of Feofol in the following countries:

• Greece

International Drug Name Search

Ferol

Ferol may be available in the countries listed below.

Ingredient matches for Ferol

Ferrous Fumarate

Ferrous Fumarate is reported as an ingredient of Ferol in the following countries:

• Venezuela

International Drug Name Search

Monotramal

Monotramal may be available in the countries listed below.

Ingredient matches for Monotramal

Tramadol

Tramadol hydrochloride (a derivative of Tramadol) is reported as an ingredient of Monotramal in the following countries:

• France

International Drug Name Search

Restoril

Restoril is a brand name of temazepam, approved by the FDA in the following formulation(s):

RESTORIL (temazepam - capsule; oral)

• 
  Manufacturer: MALLINCKRODT INC
  
  Approved Prior to Jan 1, 1982
  
  Strength(s): 15MG ^[AB], 30MG ^[RLD][AB]


• 
  Manufacturer: MALLINCKRODT INC
  
  Approval date: October 25, 1991
  
  Strength(s): 7.5MG ^[AB]


• 
  Manufacturer: MALLINCKRODT INC
  
  Approval date: November 2, 2004
  
  Strength(s): 22.5MG ^[AB]

Has a generic version of Restoril been approved?

Yes. The following products are equivalent to Restoril:

temazepam capsule; oral

• 
  Manufacturer: ACTAVIS ELIZABETH
  
  Approval date: August 7, 1987
  
  Strength(s): 15MG ^[AB], 30MG ^[AB]


• 
  Manufacturer: MUTUAL PHARM
  
  Approval date: September 8, 2009
  
  Strength(s): 7.5MG ^[AB]


• 
  Manufacturer: MUTUAL PHARM
  
  Approval date: September 14, 2009
  
  Strength(s): 22.5MG ^[AB]


• 
  Manufacturer: MYLAN
  
  Approval date: July 7, 1986
  
  Strength(s): 15MG ^[AB]


• 
  Manufacturer: MYLAN
  
  Approval date: July 10, 1986
  
  Strength(s): 30MG ^[AB]


• 
  Manufacturer: MYLAN
  
  Approval date: June 12, 2009
  
  Strength(s): 22.5MG ^[AB]


• 
  Manufacturer: MYLAN
  
  Approval date: May 21, 2010
  
  Strength(s): 7.5MG ^[AB]


• 
  Manufacturer: NOVEL LABS INC
  
  Approval date: April 21, 1987
  
  Strength(s): 15MG ^[AB], 30MG ^[AB]


• 
  Manufacturer: SANDOZ
  
  Approval date: January 12, 1988
  
  Strength(s): 15MG ^[AB], 30MG ^[AB]


• 
  Manufacturer: WATSON LABS
  
  Approval date: May 21, 1993
  
  Strength(s): 15MG ^[AB], 30MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Restoril. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Restoril.

See also...

• Restoril Consumer Information (Drugs.com)
• Restoril Consumer Information (Wolters Kluwer)
• Restoril Consumer Information (Cerner Multum)
• Restoril Advanced Consumer Information (Micromedex)
• Restoril AHFS DI Monographs (ASHP)
• Temazepam Consumer Information (Drugs.com)
• Temazepam Consumer Information (Wolters Kluwer)
• Temazepam Consumer Information (Cerner Multum)
• Temazepam Advanced Consumer Information (Micromedex)
• Temazepam AHFS DI Monographs (ASHP)

Tri-Gynera

Tri-Gynera may be available in the countries listed below.

Ingredient matches for Tri-Gynera

Ethinylestradiol

Ethinylestradiol is reported as an ingredient of Tri-Gynera in the following countries:

• Portugal

Gestodene

Gestodene is reported as an ingredient of Tri-Gynera in the following countries:

• Portugal

International Drug Name Search

BMD

Dosage Form: FOR ANIMAL USE ONLY
BMD®

30 Granular A

Bacitracin Methylene Disalicylate

Type A Medicated Article

Antibacterial

For supplementing rations of swine, chickens, turkeys, pheasants, quail and feedlot beef cattle

Active drug ingredient

Each pound contains feed grade bacitracin methylene disalicylate equivalent to 30 grams bacitracin (Master Standard).

Composition

A dried precipitated fermentation product obtained by culturing B. licheniformis Tracy on media adapted for microbiological production of bacitracin; calcium carbonate.

For manufacturing medicated poultry and livestock feeds only

Mixing directions

Prepare an intermediate premix containing 5 grams per pound by mixing 1.0 lb of BMD 30 Granular A with 5.0 lbs of soybean meal or ground corn. Then add 0.8 to 50 lbs of intermediate premix per ton of finished feed.

Species	Grams bacitracin per ton of feed	Indications for Use
Growing/ finishing swine	10 - 30	For increased rate of weight gain and improved feed efficiency.
	250	For control of swine dysentery (bloody scours) associated with Treponema hyodysenteriae in pigs up to 250 lbs body weight. Feed 250 grams per ton of complete feed on premises with a history of swine dysentery, but where signs of the disease have not yet occurred or following an approved treatment of the disease condition.
		The 250 g/ton level will provide 5 to 7 mg/lb in swine weighing 40 to 250 lbs.
		CAUTION: Diagnosis should be confirmed by a veterinarian when results are not satisfactory. Feed containing an approved level of bacitracin methylene disalicylate should be the sole ration.
Pregnant sows	250	For control of clostridial enteritis caused by C. perfringens in suckling piglets when fed to sows from 14 days before through 21 days after farrowing on premises with a history of clostridial scours.
		CAUTION: Diagnosis should be confirmed by a veterinarian when results are not satisfactory. Feed containing an approved level of bacitracin methylene disalicylate should be the sole ration.
Broiler and replacement chickens	4 - 50	For increased rate of weight gain and improved feed efficiency.
	50	As an aid in prevention of necrotic enteritis caused or complicated by Clostridium spp. or other organisms susceptible to bacitracin methylene disalicylate.
	100 - 200	As an aid in control of necrotic enteritis caused or complicated by Clostridium spp. or other organisms susceptible to bacitracin methylene disalicylate.
		CAUTION: To control a necrotic enteritis outbreak, start medication at the first clinical signs of disease. The dosage range permitted provides for different levels based on severity of the infection. Consult a poultry diagnostic laboratory or pathologist to determine the diagnosis and advice regarding the optimal level of drug. Administer continuously for 5 - 7 days or as long as clinical signs persist, and then reduce medication to prevention level (50 g/ton).
Laying hens	10 - 25	For increased egg production and improved feed efficiency during the first seven months of production.
Growing turkeys	4 - 50	For increased rate of weight gain and improved feed efficiency.
	200	As an aid in control of transmissible enteritis in growing turkeys complicated by organisms susceptible to bacitracin methylene disalicylate.
Pheasants	4 - 50	For increased rate of weight gain and improved feed efficiency.
Quail	5 - 20	For increased rate of weight gain and improved feed efficiency in quail not over 5 weeks of age.
	200	For prevention of ulcerative enteritis in growing quail due to Clostridium colinum susceptible to bacitracin methylene disalicylate. Feed continuously as the sole ration.
Feedlot beef cattle	mg/head/day
	70 (continuously)	For reduction in the number of liver condemnations due to abscesses in feedlot beef cattle.
	250 (5 days in 30)	For reduction in the number of liver condemnations due to abscesses in feedlot beef cattle.

Note: Where minimum levels are shown, increase the antibiotic concentration within approved range when necessary to fit the feeding program, and to ensure adequate levels of antibiotic in the complete ration.

Restricted Drug (California) - Use only as directed.

For Use in Animals Only.

For Use in Dry Feeds Only.

Not for Use in Liquid Medicated Feeds.

NADA 46-592, Approved by FDA

Marketed by

Alpharma, LLC

Bridgewater, New Jersey 08807

Net wt 50 LB (22.68 kg)

Trademarks registered

by Alpharma, LLC

099316 1008

PRINCIPAL DISPLAY PANEL-22.68 kg Bag Label

BMD®

30 Granular A

ALPHARMA

Bacitracin Methylene Disalicylate

Type A Medicated Article

Antibacterial

See mixing directions, claims, cautions

and warnings on back

Net wt 50 LB (22.68 kg)

ALPHARMA®

BMD  bacitracin methylene disalicylate  granule

Product Information Product Type OTC TYPE A MEDICATED ARTICLE ANIMAL DRUG NDC Product Code (Source) 46573-132 Route of Administration ORAL DEA Schedule

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength Bacitracin Methylene Disalicylate (Bacitracin) Bacitracin Methylene Disalicylate 30 g  in 0.45 kg

Inactive Ingredients Ingredient Name Strength Calcium Carbonate

Product Characteristics Color GRAY (Gray to Brown) Score      Shape Size Flavor Imprint Code Contains

Packaging # NDC Package Description Multilevel Packaging 1 46573-132-00 22.68 kg In 1 BAG None

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NADA	NADA046592	02/05/2011

Labeler - Alpharma, LLC. (070954094)

Revised: 02/2011Alpharma, LLC.

Acido Alendronico Ciclum

Acido Alendronico Ciclum may be available in the countries listed below.

Ingredient matches for Acido Alendronico Ciclum

Alendronic Acid

Alendronic Acid is reported as an ingredient of Acido Alendronico Ciclum in the following countries:

• Portugal

International Drug Name Search

Duramist Plus

Generic Name: oxymetazoline (Nasal route)

ox-i-me-TAZ-oh-leen

Commonly used brand name(s)

In the U.S.

• 4-Way Long Lasting


• Afrin


• Duramist Plus


• Duration


• Genasal


• Mucinex Full Force


• Mucinex Moisture Smart


• Nasacon


• Nasin


• Neo-Synephrine 12 Hour


• Nostrilla


• NRS-Nasal Relief


• Sinarest Nasal


• Vicks Sinex 12 Hour

Available Dosage Forms:

• Solution


• Spray

Therapeutic Class: Decongestant

Chemical Class: Imidazoline

Uses For Duramist Plus

Oxymetazoline is used for the temporary relief of nasal (of the nose) congestion or stuffiness caused by hay fever or other allergies, colds, or sinus trouble.

This medicine may also be used for other conditions as determined by your doctor.

This medicine is available without a prescription.

Before Using Duramist Plus

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Children may be especially sensitive to the effects of oxymetazoline. This may increase the chance of side effects during treatment.

Geriatric

Many medicines have not been tested in older people. Therefore, it may not be known whether they work exactly the same way they do in younger adults or if they cause different side effects or problems in older people. There is no specific information about the use of oxymetazoline in the elderly.

Breast Feeding

There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.

Interactions with Medicines

Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.

Interactions with Food/Tobacco/Alcohol

Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.

Other Medical Problems

The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:

• Type 2 diabetes mellitus

• Dry membranes in nose

• Enlarged prostate—Difficulty urinating may worsen

• Glaucoma

• Heart or blood vessel disease or


• High blood pressure—Oxymetazoline may make the condition worse

• Overactive thyroid

Proper Use of oxymetazoline

This section provides information on the proper use of a number of products that contain oxymetazoline. It may not be specific to Duramist Plus. Please read with care.

To use the nose drops:

• Blow your nose gently. Tilt the head back while standing or sitting up, or lie down on a bed and hang the head over the side. Place the drops into each nostril and keep the head tilted back for a few minutes to allow the medicine to spread throughout the nose.


• Rinse the dropper with hot water and dry with a clean tissue. Replace the cap right after use.


• To avoid spreading the infection, do not use the container for more than one person.

To use the nose spray:

• Blow your nose gently. With the head upright, spray the medicine into each nostril. Sniff briskly while squeezing the bottle quickly and firmly. For best results, spray once into each nostril, wait 3 to 5 minutes to allow the medicine to work, then blow the nose gently and thoroughly. Repeat until the complete dose is used.


• Rinse the tip of the spray bottle with hot water, taking care not to suck water into the bottle, and dry with a clean tissue. Replace the cap right after use.


• To avoid spreading the infection, do not use the container for more than one person.

Use this medicine only as directed. Do not use more of it, do not use it more often, and do not use it for longer than 3 days without first checking with your doctor. To do so may make your runny or stuffy nose worse and may also increase the chance of side effects.

Dosing

The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.

The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.

• For nasal dosage form (nose drops or spray):
  
  • For nasal congestion or stuffiness:
    
    • Adults and children 6 years of age and older—Use 2 or 3 drops or sprays of 0.05% solution in each nostril every ten to twelve hours. Do not use more than two times in twenty four hours.
    
    
    • Children up to 6 years of age—Use and dose must be determined by your doctor.
    
    
  
  

Missed Dose

If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.

Storage

Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.

Keep out of the reach of children.

Do not keep outdated medicine or medicine no longer needed.

Duramist Plus Side Effects

Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor as soon as possible if any of the following side effects occur:

Symptoms of too much medicine being absorbed into the body

• Blurred vision


• fast, irregular, or pounding heartbeat


• headache, dizziness, drowsiness, or lightheadedness


• high blood pressure


• nervousness


• trembling


• trouble in sleeping


• weakness.

• Increase in runny or stuffy nose

The above side effects are more likely to occur in children because there is a greater chance in children that too much of this medicine may be absorbed into the body.

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

• Burning, dryness, or stinging inside of nose


• increase in nasal discharge


• sneezing

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: Duramist Plus side effects (in more detail)

The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.

The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.

More Duramist Plus resources

• Duramist Plus Side Effects (in more detail)
• Duramist Plus Use in Pregnancy & Breastfeeding
• Duramist Plus Drug Interactions
• Duramist Plus Support Group
• 0 Reviews for Duramist Plus - Add your own review/rating

• Duramist Plus Concise Consumer Information (Cerner Multum)


• Afrin Solution MedFacts Consumer Leaflet (Wolters Kluwer)

Compare Duramist Plus with other medications

• Nasal Congestion

Loperamid-ratiopharm

Loperamid-ratiopharm may be available in the countries listed below.

Ingredient matches for Loperamid-ratiopharm

Loperamide

Loperamide is reported as an ingredient of Loperamid-ratiopharm in the following countries:

• Lithuania


• Luxembourg

Loperamide hydrochloride (a derivative of Loperamide) is reported as an ingredient of Loperamid-ratiopharm in the following countries:

• Austria


• Estonia


• Germany

International Drug Name Search

Silina

Silina may be available in the countries listed below.

Ingredient matches for Silina

Ampicillin

Ampicillin is reported as an ingredient of Silina in the following countries:

• Turkey

Ampicillin trihydrate (a derivative of Ampicillin) is reported as an ingredient of Silina in the following countries:

• Ethiopia

International Drug Name Search

Codipar

Codipar may be available in the countries listed below.

UK matches:

• Codipar 15mg/500mg Effervescent Tablets (SPC)
• Codipar 15mg/500mg Effervescent Tablets (SPC)
• Codipar Caplets 15/500 (SPC)

Ingredient matches for Codipar

Codeine

Codeine phosphate hemihydrate (a derivative of Codeine) is reported as an ingredient of Codipar in the following countries:

• Poland


• United Kingdom

Paracetamol

Paracetamol is reported as an ingredient of Codipar in the following countries:

• Poland


• United Kingdom

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.

Filantor

Filantor may be available in the countries listed below.

Ingredient matches for Filantor

Torasemide

Torasemide is reported as an ingredient of Filantor in the following countries:

• Spain

International Drug Name Search

Enalapril La Sante

Enalapril La Sante may be available in the countries listed below.

Ingredient matches for Enalapril La Sante

Enalapril

Enalapril is reported as an ingredient of Enalapril La Sante in the following countries:

• Peru

International Drug Name Search

C1 Esterase Inhibitor, human

ATC (Anatomical Therapeutic Chemical Classification)

B02AB03

CAS registry number (Chemical Abstracts Service)

0080295-38-1

Therapeutic Categories

Hemostatic agent: antifibrinolytic

Treatment of hereditary angioedema

Chemical Name

C₁-inhibitor, human

Foreign Names

• Humaner C1-Esterase-Inhibitor (German)
• Inhibidor de la C1 esterasa humana (Spanish)

Generic Name

• Complement C1 esterase inhibitor (IS)

Brand Names

• Berinert
  Aventis, Argentina; CSL Behring, Austria; CSL Behring, Switzerland; CSL Behring, Germany; CSL Behring, Spain; CSL Behring, United Kingdom; CSL Behring, Hungary; CSL Behring, Sweden; CSL Behring, Slovakia; CSL Behring, United States; IFET, Greece



• Cetor
  Sanquin, Netherlands



• Cinryze
  Lev, United States

International Drug Name Search

Glossary

IS	Inofficial Synonym

Click for further information on drug naming conventions and International Nonproprietary Names.

GenRX Trimethoprim with Sulfamethoxazole

GenRX Trimethoprim with Sulfamethoxazole may be available in the countries listed below.

Ingredient matches for GenRX Trimethoprim with Sulfamethoxazole

Sulfamethoxazole

Sulfamethoxazole is reported as an ingredient of GenRX Trimethoprim with Sulfamethoxazole in the following countries:

• Australia

Trimethoprim

Trimethoprim is reported as an ingredient of GenRX Trimethoprim with Sulfamethoxazole in the following countries:

• Australia

International Drug Name Search

Gycerin F

Gycerin F may be available in the countries listed below.

Ingredient matches for Gycerin F

Fructose

Fructose is reported as an ingredient of Gycerin F in the following countries:

• Japan

Glycerol

Glycerol is reported as an ingredient of Gycerin F in the following countries:

• Japan

International Drug Name Search

Dialgyl

Dialgyl may be available in the countries listed below.

Ingredient matches for Dialgyl

Granisetron

Granisetron hydrochloride (a derivative of Granisetron) is reported as an ingredient of Dialgyl in the following countries:

• Greece

International Drug Name Search

Gefitinib

In the US, Gefitinib (gefitinib systemic) is a member of the drug class EGFR inhibitors and is used to treat Non-Small Cell Lung Cancer.

US matches:

• Gefitinib

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L01XE02

CAS registry number (Chemical Abstracts Service)

0184475-35-2

Chemical Formula

C22-H24-Cl-F-N4-O3

Molecular Weight

446

Therapeutic Category

Antineoplastic agent

Chemical Names

4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin)propoxy]- (USAN)

N-(3-Chlor-4-fluorphenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]chinazolin-4-amin (IUPAC)

N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine (WHO)

Foreign Names

• Gefitinibum (Latin)
• Gefitinib (German)
• Gefitinib (French)
• Gefitinib (Spanish)

Generic Names

• Gefitinib (OS: USAN, BAN)
• ZD 1839 (IS)

Brand Names

• Geftib
  Glenmark, India



• Geftinat
  Natco, India



• Iressa
  AstraZeneca, Argentina; AstraZeneca, Austria; AstraZeneca, Australia; AstraZeneca, Bahrain; AstraZeneca, Canada; AstraZeneca, Switzerland; AstraZeneca, Chile; AstraZeneca, China; AstraZeneca, Germany; AstraZeneca, Spain; AstraZeneca, France; AstraZeneca, United Kingdom; AstraZeneca, Georgia; AstraZeneca, Greece; AstraZeneca, Hong Kong; AstraZeneca, Indonesia; AstraZeneca, Israel; AstraZeneca, Japan; AstraZeneca, Mexico; AstraZeneca, Malaysia; AstraZeneca, New Zealand; AstraZeneca, Philippines; AstraZeneca, Serbia; AstraZeneca, Russian Federation; AstraZeneca, Singapore; AstraZeneca, Thailand; AstraZeneca, Taiwan; AstraZeneca, United States



• IRESSA
  AstraZeneca, Sweden

International Drug Name Search

Glossary

BAN	British Approved Name
IUPAC	International Union of Pure and Applied Chemistry
IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name
WHO	World Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Suniderma

Suniderma may be available in the countries listed below.

Ingredient matches for Suniderma

Hydrocortisone

Hydrocortisone aceponate (a derivative of Hydrocortisone) is reported as an ingredient of Suniderma in the following countries:

• Spain

International Drug Name Search

Viccilin

Viccilin may be available in the countries listed below.

Ingredient matches for Viccilin

Ampicillin

Ampicillin trihydrate (a derivative of Ampicillin) is reported as an ingredient of Viccilin in the following countries:

• Thailand

International Drug Name Search

Voltarène

Voltarène may be available in the countries listed below.

Ingredient matches for Voltarène

Diclofenac

Diclofenac is reported as an ingredient of Voltarène in the following countries:

• Tunisia

Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Voltarène in the following countries:

• France

International Drug Name Search

Budesonide Powder

Generic Name: Budesonide (byoo-DESS-oh-nide)
Brand Name: Pulmicort Turbuhaler

Use caution if you switch from an oral steroid (eg, prednisone) to Budesonide Powder. It may take several months for your body to make enough natural steroids to handle events that cause physical stress. Such events may include injury, surgery, infection, loss of blood electrolytes, or a sudden asthma attack. These may be severe and sometimes fatal. Contact your doctor right away if any of these events occur. You may need to take an oral steroid (eg, prednisone) again.

Carry a card at all times that says you may need an oral steroid (eg, prednisone) if any of these events occur.

Budesonide Powder is used for:

Preventing asthma in adults and children 6 years of age or older. It may also be used in patients who require oral corticosteroid medicine. It is not used to relieve an asthma attack. It may also be used for other conditions as determined by your doctor.

Budesonide Powder is an inhaled corticosteroid. It works by decreasing the irritation and swelling of the breathing tubes (bronchioles) of the lung to control or prevent asthma symptoms.

Do NOT use Budesonide Powder if:

• you are allergic to any ingredient in Budesonide Powder


• you are having an acute asthma attack


• you are taking mifepristone

Contact your doctor or health care provider right away if any of these apply to you.

Before using Budesonide Powder:

Some medical conditions may interact with Budesonide Powder. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have glaucoma; cataracts; a herpes eye infection; a bacterial, fungal, parasitic, or viral infection; diarrhea; measles; tuberculosis; chicken pox; or shingles


• if you have had a positive TB skin test or have recently been vaccinated

Some MEDICINES MAY INTERACT with Budesonide Powder. Tell your health care provider if you are taking any other medicines, especially any of the following:

• Barbiturates (eg, phenobarbital), carbamazepine, hydantoins (eg, phenytoin), or rifampin because they may decrease Budesonide Powder's effectiveness


• Clarithromycin, steroidal contraceptives (eg, birth control pills), or imidazole antifungals (eg, ketoconazole, itraconazole) because they may increase the risk of Budesonide Powder's side effects


• Ritodrine or live vaccines because the risk of their side effects may be increased by Budesonide Powder


• Hydantoins (eg, phenytoin) because their effectiveness may be decreased by Budesonide Powder


• Mifepristone because risk of side effects may be increased

This may not be a complete list of all interactions that may occur. Ask your health care provider if Budesonide Powder may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Budesonide Powder:

Use Budesonide Powder as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• An extra patient leaflet is available with Budesonide Powder. Talk to your pharmacist if you have questions about this information.


• Budesonide Powder must be inhaled through the mouth. Do not breathe out through the inhaler.


• Before using, prime the inhaler by holding the unit in an upright position and turning the grip fully to the right, then fully to the left until it clicks.


• Do not shake the inhaler.


• While inhaling, hold the inhaler in an upright position (mouthpiece on top) during loading in order to provide the correct dose. Place the mouthpiece between your lips and inhale forcefully and deeply.


• Rinse the mouth with water (without swallowing) after each use to help prevent mouth or throat infections.


• Do not bite or chew the mouthpiece.


• Even though you do not sense or taste the powder, you should still be getting the right dose.


• Improvement in asthma control can occur within 24 hours of beginning treatment; the maximum effect of Budesonide Powder may take as long as 1 to 2 weeks, or longer. If symptoms do not improve within that period of time, contact your health care provider.


• Do not use Budesonide Powder with a spacer.


• Keep the inhaler clean and dry at all times.


• If you miss a dose of Budesonide Powder, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Budesonide Powder.

Important safety information:

• It may take several days for Budesonide Powder to work. Do not stop using Budesonide Powder without checking with your doctor.


• Budesonide Powder will not stop an asthma attack. Always carry appropriate medicine (eg, bronchodilator inhaler) in case you have an asthma attack. Contact your doctor immediately if your bronchodilator does not help you to breathe normally.


• Tell your doctor or dentist that you take Budesonide Powder before you receive any medical or dental care, emergency care, or surgery.


• Carry an ID card at all times that says you take Budesonide Powder.


• Use caution if you switch from an oral steroid (eg, prednisone) to Budesonide Powder. It may take several months for your body to make enough natural steroids to handle events that cause physical stress. Such events may include injury, surgery, infection, loss of blood electrolytes, or a sudden asthma attack. These may be severe and sometimes fatal. Contact your doctor right away if any of these events occur. You may need to take an oral steroid (eg, prednisone) again. Carry a card at all times that says you may need an oral steroid (eg, prednisone) if any of these events occur.


• Budesonide Powder may lower the ability of your body to fight infection. Avoid contact with people who have colds or infections. Tell your doctor if you notice signs of infection like fever, sore throat, rash, or chills.


• If you have not had chickenpox, shingles, or measles, avoid contact with anyone who does.


• Do not receive a live vaccine (eg, measles, mumps) while you are taking Budesonide Powder. Talk with your doctor before you receive any vaccine.


• Lab tests, including adrenal function assessment, may be performed while you use Budesonide Powder. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.


• Corticosteroids may affect growth rate in CHILDREN and teenagers in some cases. They may need regular growth checks while they use Budesonide Powder.


• Budesonide Powder should not be used in CHILDREN younger than 6 years old. Budesonide Powder should be used with extreme caution in CHILDREN 6 to 17 years old; safety and effectiveness in these children have not been confirmed.


• PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Budesonide Powder while you are pregnant. It is unknown if Budesonide Powder is found in breast milk. If you are or will be breast-feeding while you use Budesonide Powder, check with your doctor. Discuss any possible risks to your baby.

If symptoms of WITHDRAWAL occur when switching from an oral medicine to an inhaled one (muscle and joint pain, exhaustion; depression), contact your health care provider at once.

Possible side effects of Budesonide Powder:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Bad taste in mouth; back pain; cough; fever; headache; hoarseness; indigestion; nausea; pain; throat irritation.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); ear infection; fainting; increased wheezing; infection (fever, chills, sore throat); mental/mood changes; severe dizziness; shortness of breath after using Budesonide Powder; sinus infection; sudden weight loss; tightness in the lungs; vomiting; white patches in mouth or on throat.

This is not a complete list of all side effects that may occur. If you have questions or need medical advice about side effects, contact your doctor or health care provider. You may report side effects to the FDA at 1-800-FDA-1088 (1-800-332-1088) or at http://www.fda.gov/medwatch.

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (http://www.aapcc.org/DNN/), or emergency room immediately.

Proper storage of Budesonide Powder:

Store Budesonide Powder at room temperature, between 68 and 77 degrees F (20 to 25 degrees C). Store away from heat, moisture, and direct sunlight. Replace the cover after each use. Do not puncture, break, or burn the canister even if it appears to be empty. Do not store in the bathroom. Keep Budesonide Powder out of the reach of children and away from pets.

General information:

• If you have any questions about Budesonide Powder, please talk with your doctor, pharmacist, or other health care provider.


• Budesonide Powder is to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.

This information is a summary only. It does not contain all information about Budesonide Powder. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Budesonide resources

• Budesonide Use in Pregnancy & Breastfeeding
• Budesonide Drug Interactions
• Budesonide Support Group
• 22 Reviews for Budesonide - Add your own review/rating

Compare Budesonide with other medications

• Asthma, Maintenance
• Autoimmune Hepatitis
• Crohn's Disease
• Crohn's Disease, Acute
• Crohn's Disease, Maintenance
• Eosinophilic Esophagitis
• Inflammatory Bowel Disease

Termisil

Termisil may be available in the countries listed below.

Ingredient matches for Termisil

Terbinafine

Terbinafine is reported as an ingredient of Termisil in the following countries:

• Greece


• Indonesia

Terbinafine hydrochloride (a derivative of Terbinafine) is reported as an ingredient of Termisil in the following countries:

• Japan

International Drug Name Search

Bisoprololfumaraat Katwijk

Bisoprololfumaraat Katwijk may be available in the countries listed below.

Ingredient matches for Bisoprololfumaraat Katwijk

Bisoprolol

Bisoprolol fumarate (a derivative of Bisoprolol) is reported as an ingredient of Bisoprololfumaraat Katwijk in the following countries:

• Netherlands

International Drug Name Search

Urusan

Urusan may be available in the countries listed below.

Ingredient matches for Urusan

Aluminium Hydroxide

Aluminium Hydroxide is reported as an ingredient of Urusan in the following countries:

• Vietnam

Magnesium Carbonate

Magnesium Carbonate is reported as an ingredient of Urusan in the following countries:

• Vietnam

International Drug Name Search

Dexium SP Injection

Generic Name: dexamethasone sodium phosphate injection

Dosage Form: FOR ANIMAL USE ONLY

DESCRIPTION:

Dexamethasone sodium phosphate (a synthetic adrenocortical steroid), is a white or slightly yellow crystalline powder.  It is freely soluble in water and is exceedingly hygroscopic.  Each mL of sterile aqueous solution contains Dexamethasone Sodium Phosphate 4 mg (equivalent to dexamethasone 3 mg).  Sodium Citrate 10 mg, Sodium Bisulfite 2 mg, Benzyl Alcohol 1.5% as preservative, in Water for Injection q.s. Sodium Hydroxide and/or Hydrochloric Acid to adjust pH to between 7.0 and 8.5.

CLINICAL PHARMACOLOGY

Dexamethasone is a synthetic corticosteroid and possesses glucocorticoid activity.  Dexamethasone sodium phosphate is a salt of dexamethasone that is particularly suitable for intravenous administration because it is highly water soluble, permitting administration of relatively large doses in a small volume of diluent.  Dexamethasone, as a steroid, is equivalent in potency to some established steroids while being considerably more potent that others.  In the case of the dog, dexamethasone is found to be about equivalent in dosage to prednisone but about 30 to 40 times more potent than prednisolone.

INDICATIONS AND USAGE

Dexamethasone Sodium Phosphate Injection is indicated as a rapid adrenal glucocorticoid and/or anti-inflammatory agent in horses.

CONTRAINDICATIONS

Do not use in viral infections.  Except when used for emergency therapy, dexamethasone sodium phosphate is contraindicated in animals with tuberculosis and chronic nephritis.  Existence of congestive heart failure, osteoporosis and diabetes are relative contraindications.  In the presence of infection appropriate antibacterial agents should also be administered and should be continued for at least 3 days after discontinuance of the hormone and disappearance of all signs of infection.

WARNINGS

Clinical and experimental data have demonstrated that corticosteroids administered orally or by injection to animals may induce the first stage of parturition if used during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis.  Additionally, corticosteroids administered to dogs, rabbits, and rodents during pregnancy have produced cleft palate.  Other congenital anomalies including deformed forelegs, phocomelia, and anasarca have been reported in offspring of dogs which received corticosteroids during pregnancy.

PRECAUTIONS

Because of the anti-inflammatory action of corticosteroids, signs of infection may be hidden and it may be necessary to stop treatment until diagnosis is made.  Overdosage of some glucocorticoids may result in sodium retention, fluid retention, potassium loss and weight gains.

In infections characterized by overwhelming toxicity, dexamethasone sodium phosphate therapy, in conjunction with indicated antibacterial therapy, is effective in reducing mortality.  It is essential that the causative organism be known and an effective antibacterial agent be administered concurrently.  The injudicious use of adrenal hormones in animals with infections can be hazardous.

Use of corticosteroids, depending on dose, duration and specific steroid, may result in inhibition of endogenous steroid production following drug withdrawal.  In patients presently receiving or recently withdrawn from systemic corticosteroid should be considered in unusually stressful situations.

Use of corticosteroids, depending on dose, duration and specific steroid, may result in inhibition of endogenous steroid production following drug withdrawal.  In patients presently receiving or recently withdrawn from systemic corticosteroid treatments, therapy with a rapidly acting corticosteroid should be considered in unusually stressful situations.

ADVERSE REACTIONS

The therapeutic use of dexamethasone sodium phosphate injection is unlikely to cause undesired accentuation of metabolic effects.  However, if continued corticosteroid therapy is anticipated, a high protein intake should be provided to keep the animal in positive nitrogen balance.  A retardant effect on wound healing should be considered when it is used in conjunction with surgery.  Euphoria or an improvement of attitude, and increased appetite are the usual manifestations.  Side effects such as glycosuria, hyperglycemia, diarrhea, polydipsia and polyuria have been observed in some species.

Side effects such as SAP and SGPT enzyme elevations, eosinopenia, and vomiting have occurred following use of synthetic corticosteroids in dogs.  Cushing's Syndrome in dogs has been reported in association with prolonged or repeated steroid therapy.

Corticosteroids reportedly cause laminitis in horses.

DOSAGE AND ADMINISTRATION

For Intravenous Use Only.

Horses:  The usual intravenous dosage is 2.5 mg to 5 mg (based on 3 mg per mL of dexamethasone content).  If permanent corticosteroid effect is required, oral therapy with dexamethasone may be substituted.  When therapy is to be withdrawn after prolonged corticosteroid administration, the daily dose should be reduced gradually over a number of days, in stepwise fashion.

HOW SUPPLIED

Dexium-SP, dexamethasone sodium phosphate injection 4 mg/mL (equivalent to 3 mg/mL dexamethasone) is available in 100 mL multiple dose vials.

Store between 15 degrees and 30 degrees C (56 degrees and 86 degrees F).  Do not freeze.

CAUTION

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Dexium-SP  Multiple Dose Vial


DEXAMETHASONE SODIUM PHOSPHATE INJECTION USP


4 mg per mL


Sterile


Equivalent to dexamethasone 3 mg/mL


FOR INTRAVENOUS USE IN HORSES ONLY


CAUTION:  Federal (U.S.A) law restricts this drug to use by or on the order of a licensed veterinarian.


ANADA #200-317 Approved by FDA


Net Contents:  100mL

DEXIUM-SP  dexamethasone sodium phosphate  injection, solution

Product Information Product Type PRESCRIPTION ANIMAL DRUG NDC Product Code (Source) 61133-0892 Route of Administration INTRAVENOUS DEA Schedule

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength Dexamethasone Sodium Phosphate (Dexamethasone) Dexamethasone 4 mg  in 1 mL

Inactive Ingredients Ingredient Name Strength Sodium Citrate   Sodium Bisulfite   Benzyl Alcohol   Water   Sodium Hydroxide   Hydrochloric Acid

Product Characteristics Color      Score      Shape Size Flavor Imprint Code Contains

Packaging # NDC Package Description Multilevel Packaging 1 61133-0892-9 100 mL In 1 VIAL, MULTI-DOSE None

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANADA	ANADA200317	04/04/2009

Labeler - Bimeda, Inc. Division of Cross Vetpharm Group (043653216)

Registrant - Bimeda, Inc. Division of Cross Vetpharm Group (043653216)

Establishment
Name	Address	ID/FEI	Operations
Bimeda-MTC Animal Health, Division of Cross Vetpharm Group		256232216	manufacture

Revised: 02/2011Bimeda, Inc. Division of Cross Vetpharm Group

Salmétérol

Salmétérol may be available in the countries listed below.

Ingredient matches for Salmétérol

Salmeterol

Salmétérol (DCF) is known as Salmeterol in the US.

International Drug Name Search

Glossary

DCF	Dénomination Commune Française

Click for further information on drug naming conventions and International Nonproprietary Names.

Nibulen

Nibulen may be available in the countries listed below.

Ingredient matches for Nibulen

Ciclopirox

Ciclopirox olamine (a derivative of Ciclopirox) is reported as an ingredient of Nibulen in the following countries:

• Turkey

International Drug Name Search

Pervone

Pervone may be available in the countries listed below.

Ingredient matches for Pervone

Dihydroergotamine

Dihydroergotamine mesilate (a derivative of Dihydroergotamine) is reported as an ingredient of Pervone in the following countries:

• Greece

International Drug Name Search

Hémi-Daonil

Hémi-Daonil may be available in the countries listed below.

Ingredient matches for Hémi-Daonil

Glibenclamide

Glibenclamide is reported as an ingredient of Hémi-Daonil in the following countries:

• France


• Tunisia

International Drug Name Search